3 August 2018
1 August 2018
Non-motor symptoms of Parkinson’s disease (PD), such as depression, apathy, cognitive impairment, sleep disorders, and sensory symptoms, can have a greater impact on health-related quality of life than motor deficits.
26 June 2018
A brand new Quarterly Parkinson's Webinar Series, delivered by JPD, CPT and Parkinson's Movement, sees the the discussion of specific Parkinson's disease research topics is brought into the open. The first webinar in our quarterly series took place on June 19, 2018 with a focus on exenatide, and the recording can now be viewed online.
8 June 2018
Parkinson's Movement – An Initiative of the CPT in association with JPD – Announces the Quarterly Parkinson's Webinar Series
We are pleased to announce that JPD is working in partnership with The Cure Parkinson’s Trust (CPT) to provide information about breaking research news to be featured on the new web portal for people with Parkinson’s (PwPs) call
13 September 2017
According to a new report in the Journal of Parkinson’s Disease, researchers identified the first case of a patient with Parkinson's disease carrying a mutation in the ACMSD gene.
31 July 2017
Constipation is one of the most common non-motor related complaints affecting Parkinson’s disease (PD) patients.
23 March 2017
Parkinson’s disease (PD) is a progressive condition that often results in mobility impairments and can lead to decreased health-related quality of life (HRQL) and death. There is evidence that physical activity can delay decline in PD patients.
23 March 2017
Journal of Parkinson’s Disease Celebrates Key Breakthroughs that Shaped PD Research over the Last 200 Years
7 March 2017
There has long been interest in whether monoamine oxidase type B (MAO-B) inhibitors slow progression of Parkinson’s disease (PD) and improve long-term outcomes. They have shown neuroprotective effects in cell culture and animal studies of PD, but clinical trial results have been mixed and have failed to convincingly demonstrate disease modifying effects in people with PD. In a retrospective analysis by Hauser et al. in the Journal of Parkinson’s Disease, researchers looked at the results from a large study and found that participants who received an MAO-B inhibitor for a longer period of time experienced slower clinical decline.
13 February 2017
ÜberResearch and Altmetric, leading data and analytics companies serving scientific funders and research organizations, have published an analysis of Parkinson’s disease research papers with the highest Altmetric Attention Scores in the Journal of Parkinson’s Disease. The publication is the first in a series aimed at utilizing Altmetric data to provide a more nuanced understanding of how the announcements of new medical discoveries affect the wide-range of disease-specific stakeholders including researchers, funders, care providers, and patients.